Insufficient scRNA-seq data for expression of ERV3-1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 99% | 1148.26 | 1435 / 1445 | 97% | 36.13 | 178 / 183 |
breast | 100% | 2071.66 | 459 / 459 | 94% | 20.09 | 1054 / 1118 |
ovary | 100% | 1041.24 | 180 / 180 | 94% | 16.57 | 403 / 430 |
lung | 100% | 1182.44 | 577 / 578 | 92% | 18.19 | 1060 / 1155 |
prostate | 99% | 840.59 | 243 / 245 | 88% | 8.59 | 442 / 502 |
thymus | 100% | 1100.31 | 651 / 653 | 85% | 7.48 | 514 / 605 |
adrenal gland | 100% | 4109.79 | 258 / 258 | 83% | 10.84 | 191 / 230 |
bladder | 95% | 810.95 | 20 / 21 | 76% | 12.60 | 384 / 504 |
pancreas | 89% | 427.13 | 293 / 328 | 81% | 10.32 | 144 / 178 |
stomach | 92% | 569.18 | 332 / 359 | 77% | 11.47 | 219 / 286 |
intestine | 97% | 675.11 | 941 / 966 | 70% | 9.24 | 371 / 527 |
kidney | 98% | 594.92 | 87 / 89 | 69% | 5.12 | 621 / 901 |
brain | 77% | 376.23 | 2045 / 2642 | 87% | 7.75 | 612 / 705 |
uterus | 100% | 1039.08 | 170 / 170 | 64% | 8.88 | 292 / 459 |
skin | 99% | 1099.29 | 1790 / 1809 | 48% | 3.57 | 226 / 472 |
adipose | 100% | 2331.67 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 715.68 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 960.10 | 1321 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 717.16 | 860 / 929 | 0% | 0 | 0 / 0 |
heart | 88% | 484.15 | 754 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 67% | 4.33 | 30 / 45 |
eye | 0% | 0 | 0 / 0 | 64% | 3.65 | 51 / 80 |
muscle | 53% | 229.63 | 428 / 803 | 0% | 0 | 0 / 0 |
liver | 32% | 102.37 | 72 / 226 | 18% | 1.16 | 75 / 406 |
lymph node | 0% | 0 | 0 / 0 | 48% | 3.57 | 14 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008150 | Biological process | biological_process |
GO_0003674 | Molecular function | molecular_function |
Gene name | ERV3-1 |
Protein name | Endogenous retrovirus group 3 member 1 Env polyprotein (ERV-3 envelope protein) (ERV3 envelope protein) (ERV3-1 envelope protein) (Envelope polyprotein) (HERV-R envelope protein) (ERV-R envelope protein) (HERV-R_7q21.2 provirus ancestral Env polyprotein) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)] |
Synonyms | ERV3 |
Description | FUNCTION: Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its fusogenic properties. It can inhibit cell growth through decrease expression of cyclin B1 and increased expression of p21 in vitro. .; FUNCTION: SU mediates receptor recognition. .; FUNCTION: TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity). . |
Accessions | Q14264 ENST00000394323.3 |